Guidant
This article was originally published in The Gray Sheet
Executive Summary
Enrollment in the firm's 1,042-patient, 70-center DELIVER trial to evaluate effectiveness of the paclitaxel-coated Multi-Link Penta stent compared to an uncoated version is expected to begin in mid-November following submission of an investigational device exemption application, announced Oct. 8. Nine-month follow-up is expected by the fourth quarter of 2002. Separately, Guidant announces CE mark approval for the Insignia pacemaker line, European launch of the Acculink carotid stent system and worldwide launch of the second-generation Viatrac 14 Plus peripheral dilatation catheter for treatment of blockages of peripheral arteries
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.